Clinical Trial Detail

NCT ID NCT00718263
Title Efficacy and Safety of Nilotinib Patients With Newly Diagnosed CML - CP (Chronic Myelogenous Leukemia - Chronic Phase)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements yes
Sponsors Novartis Pharmaceuticals
Indications

chronic myeloid leukemia

Therapies

Imatinib

Nilotinib

Age Groups: adult

Additional content available in CKB BOOST